Dr. Robert Hrubiec is an intellectual property attorney with over 25 years’ experience in all aspects of intellectual property, specializing in pharmaceutical, biotechnology and medical device/diagnostic patent management, strategic IP evaluation, litigation support, business development, mergers/acquisitions, licensing, FDA regulations, trademarks and patent preparation and prosecution. Dr. Hrubiec is currently the Consulting Intellectual Property Counsel for Panavance Therapeutics and is primarily responsible for providing general intellectual property consulting services, evaluating the company’s patents and patent applications, providing creative patent strategies to further protect key technologies and making intellectual property recommendations to upper management. Dr. Hrubiec is also the founder and President of Innoventiv IP, an intellectual property management and consulting company focused on advising high technology companies on legal matters, patent portfolio management, strategic planning, life-cycle management, licensing/acquisitions/confidentiality/clinical trial and other agreements, due diligence, maximizing value, cost reduction and litigation support. Prior to founding Innoventiv IP in 2012, Dr. Hrubiec was Vice President and Chief Intellectual Property Counsel at Cephalon, Inc., where he was responsible for creating, developing and managing the company’s global IP department as well as all IP aspects of business development. Prior to joining Cephalon in 1999, Dr. Hrubiec was an intellectual property attorney with GlaxoSmithKline and directed a research laboratory at Cytogen Corporation focused on cytotoxic agents conjugated to monoclonal antibodies for use in treating cancer. Dr. Hrubiec received his Ph.D. in synthetic organic chemistry from the University of Connecticut followed by a postdoctoral fellowship in pharmacology/molecular biology at the Yale Medical School Comprehensive Cancer Center. He obtained his law degree from the North Carolina Central University School of Law and is licensed in North Carolina, Pennsylvania and the USPTO.